Michael Cloud, MD
Internal Medicine · Little Rock, ARNPI 1598184970
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 714 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,048, 5.2 times the $392 reported in 2019. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $13.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- GSK$868
- Lilly USA, LLC$703
- Abbott$630
- Novo Nordisk$440
- plus $4K from 40 others
What the payments were for
- Food & beverage$9,952100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,958 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $139,648 |
| JardianceEmpagliflozin | 75 | $78,453 |
| MounjaroTirzepatide | 44 | $62,816 |
| FarxigaDapagliflozin Propanediol | 33 | $44,874 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $42,484 |
| VraylarCariprazine Hcl | 22 | $38,710 |
| RexultiBrexpiprazole | 25 | $36,860 |
| EliquisApixaban | 49 | $35,131 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $34,461 |
| UbrelvyUbrogepant | 27 | $34,403 |
| XareltoRivaroxaban | 31 | $28,530 |
| LinzessLinaclotide | 27 | $23,925 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $22,846 |
| Nurtec OdtRimegepant Sulfate | 23 | $22,754 |
| JanuviaSitagliptin Phosphate | 17 | $20,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $440 | $156,534119 claims |
| AbbVieVraylar, Ubrelvy, Linzess | $1,901 | $97,03776 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $868 | $89,436132 claims |
| Lilly USA, LLCMounjaro, Trulicity | $703 | $80,02157 claims |
| Boehringer IngelheimJardiance | $62 | $78,45375 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,207 | $74,52089 claims |
| PfizerEliquis, Nurtec Odt | $381 | $57,88572 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $269 | $36,86025 claims |
| MerckJanuvia, Belsomra | $158 | $29,90629 claims |
| Johnson & JohnsonXarelto | $28 | $28,53031 claims |
| Astellas Pharma US IncMyrbetriq | $198 | $14,10921 claims |
| Sanofi-aventis U.S. LLCLantus | $28 | $2,43812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Little Rock
- Aaron StrobelLittle Rock$32K
- Jeremy DavisLittle Rock$17K
- Ritesh RampureLittle Rock$13K
- Milton RoachLittle Rock$12K
- Saul Rios HerreraLittle Rock$8K
- Zhangning ChenLittle Rock$8K
- Russell RoarkLittle Rock$7K
- Arpana EdalaLittle Rock$6K
- Srikanth VallurupalliLittle Rock$5K
- Devendra PatelLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.